Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Synergistic efficacy and preliminary molecular mechanisms of venetoclax combined with microtransplantation in the treatment of elderly patients with Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYuxian HuangJWJiayue WeiZLZiwei Liu

Discussion

Loading...

Member takes

Overview

Efficacy analysis shows 77.8% overall survival in elderly AML patients, suggesting combined therapy enhances cytotoxicity.

Key Points

  • Overall survival rate of 77.8% observed in elderly patients with acute myeloid leukemia.
  • Survival analysis based on 18 patients indicated median overall survival of 53.0 months.
  • A consolidation therapy regimen involved venetoclax combined with microtransplantation for improved outcomes.
  • Results highlight the potential of targeted therapy and immunotherapy in enhancing treatment efficacy in AML.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2eehttps://doi.org/10.1182/blood-2025-7794
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation2025 · 4 citations
  2. 2Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia2025
  3. 3Real-world outcomes of venetoclax-based therapy vs intensive chemotherapy in older adults with newly diagnosed Acute Myeloid Leukemia2025
  4. 4The efficacy and safety of venetoclax-based and anthracycline-free induction therapy followed by allogeneic hematopoietic stem cell transplantation in the treatment of transplant-eligible Acute Myeloid Leukemia patients2025
  5. 5Factors affecting response and resistance to venetoclax in acute myeloid leukemia2025 · 6 citations